However, we identified pre-existing BRAF amplification in a treatment-naive BRAF mutant colorectal cancer, suggesting that BRAF amplification could also be a cause of de novo resistance to BRAF and MEK inhibitors in the clinic. The gene discussed is MAP2K7; the disease is colorectal cancer.